Showing results (151-160 of 264) with videos related to

Sort By:
Pageof 27
Anticancer Research|May 18, 2012
The survivin suppressant YM155 potentiates chemosensitivity to gemcitabine in the human pancreatic cancer cell line MiaPaCa-2Dok Hyun Yoon, Jae-Sik Shin, Dong-Hoon Jin, et al.
Scientific Reports|February 4, 2021
Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disorders-diffuse large B-cell lymphomaJwa Hoon Kim, Hyungwoo Cho, Heungsup Sung, et al.
Frontiers in Oncology|March 29, 2020
Risk Stratification Using Multivariable Fractional Polynomials in Diffuse Large B-Cell LymphomaJin Roh, Jiwon Jung, Yourim Lee, et al.
International Journal of Radiation Oncology, Biology, Physics|August 3, 2010
Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving sequential induction chemotherapy followed by concurrent chemoradiotherapyDok Hyun Yoon, Yoojin Cho, Sang Yoon Kim, et al.
International Journal of Radiation Oncology, Biology, Physics|February 15, 2015
Randomized phase 2 trial of S1 and oxaliplatin-based chemoradiotherapy with or without induction chemotherapy for esophageal cancerDok Hyun Yoon, Geundoo Jang, Jong Hoon Kim, et al.
European Journal of Haematology|February 18, 2015
TCL1 expression predicts overall survival in patients with mantle cell lymphomaSu-Jin Shin, Jin Roh, Hee Jeong Cha, et al.
Cancer Research and Treatment|February 16, 2019
Body Cavity-Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of LymphomaJunghoon Shin, Young Hyeh Ko, Sung Yong Oh, et al.
Plos One|June 23, 2012
YM155 induces EGFR suppression in pancreatic cancer cellsYoung-Soon Na, Soo-Jin Yang, Seung-Mi Kim, et al.
Experimental Hematology|September 2, 2015
Induction chemotherapy followed by up-front autologous stem cell transplantation may have a survival benefit in high-risk diffuse large B-cell lymphoma patientsHo-Jin Shin, Dok Hyun Yoon, Ho Sup Lee, et al.
Annals of Hematology|April 26, 2020
A phase II study of ibrutinib in combination with rituximab-cyclophosphamide-doxorubicin hydrochloride-vincristine sulfate-prednisone therapy in Epstein-Barr virus-positive, diffuse large B cell lymphoma (54179060LYM2003: IVORY study): results of the final analysisSang Eun Yoon, Seok Jin Kim, Dok Hyun Yoon, et al.
Pageof 27